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HHuntington’s disease (HD) is an autosomal dominant neurodegenerative disease and is diagnosed in part by determining the number of cytosine-adenine-guanine (CAG) trinucleotide repeats located within the huntingtin (HTT) gene on chromosome four.1 
HD is often characterized by affective and 
cognitive symptoms, in early and middle stages, 
in addition to progressive chorea, which might 
be replaced by bradykinesia, rigidity, and 
dystonia in late stages.2,3 The degree of chorea 
is associated with fluctuations in dopamine 
(DA) release and DA receptor sensitivity and 
might follow a biphasic model over the course 
of the disease.4 Though cognitive, psychiatric, 
and sleep disturbances are common in HD,5–7 
clinical trials evaluating medications have been 
challenging due to the rarity of disease 
and high drop-out rates.8 Therefore, while 
antidepressants and psychostimulants have 
been recommended for affective symptoms, 
the effects of these medications are not well 
understood.9 Pharmacotherapy for insomnia 
in HD is even less studied. As antidepressants, 
psychostimulants, and melatonin can alter 
dopaminergic regulation, it is plausible they 
could alter the chorea phenotype when used in 
patients with HD.10–13 We describe a male patient 
with previously undiagnosed HD who presented 
with significant choreoathetoid movements that 
significantly improved upon discontinuation of 
fluoxetine and lisdexamfetamine at hospital 
admission. The patient’s chorea additionally 
worsened after a two-day trial of melatonin 
during hospitalization. This report is the second 
to describe worsening chorea in a patient with 
HD following fluoxetine and psychostimulant 
use and is the first following melatonin use.13,14
CASE REPORT
A 52-year-old Caucasian male presented 
with police to the emergency room after 
allegedly becoming increasingly disruptive, 
physically intrusive, and assaulting staff at 
his assisted living facility. He was admitted 
to the neurobehavioral medicine inpatient 
unit for further evaluation. Past psychiatric 
history was significant for two psychiatric 
hospitalizations within the past 3.5 years in the 
context of personality change, neurocognitive 
dysfunction, and mild movement abnormalities. 
During previous admissions, frontotemporal or 
progressive cortical dementia was suspected 
but not confirmed, and magnetic resonance 
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A B S T R A C T
Cognitive, affective, and sleep disturbances 
can be found in patients with Huntington’s 
disease (HD), and medications used to treat 
these HD-related sequela can also impact 
HD-related movement disorders. We present 
the case of a 52-year-old Caucasian man with 
previously undiagnosed HD who exhibited 
significant choreoathetoid movements that 
improved with discontinuation of fluoxetine 
and lisdexamfetamine upon hospital admission. 
Following diagnosis of HD through genetic 
testing, he was administered 5mg of oral 
melatonin on two consecutive evenings, which 
resulted in worsening choreoathetosis. We 
calculated Naranjo adverse event scores of 
5, 5, and 2 for fluoxetine, lisdexamfetamine, 
and melatonin, respectively, based on our 
assessment, review of outpatient medical 
records, and available literature. We review 
the literature surrounding these possible 
adverse drug events and their mechanisms 
regarding dopaminergic modulation in early-
middle stages of HD. Our report indicates that 
caution should be exercised when initiating 
psychostimulants, fluoxetine, and melatonin in 
patients with early-middle stage HD. Screening 
for HD might be warranted for patients who 
develop choreoathetosis after initiation of the 
aforementioned medications. We recommend 
ascertaining baseline level of chorea before 
initiating these medications in patients 
with known HD and closely monitoring for 
exacerbation during therapy.
KEYWORDS: Fluoxetine, antidepressant, 
psychostimulant, amphetamine, melatonin, 
Huntington’s disease, chorea, and dopamine
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imaging (MRI) showed generalized cerebral 
atrophy. During the current hospitalization, 
he demonstrated significant choreoathetoid 
movements, dysarthria, and moderately 
disorganized thought process on admission. 
Neurology was consulted due to suspected HD, 
and a HD deoxyribonucleic acid (DNA) sequence 
was ordered. Additionally, physical therapy 
utilizing strengthening exercises, a walker, and 
weights placed on all four extremities to control 
involuntary movements was initiated, which 
only resulted in mild improvement. 
His medications at admission included 
fluoxetine 60mg daily, clonazepam 0.5mg 
twice daily, olanzapine 7.5mg nightly, 
lisdexamfetamine 40mg daily, and 
fluconazole 200mg weekly for onychomycosis. 
Lisdexamfetamine and fluconazole were 
discontinued on Hospital Day 1 due to lack of 
strong indication and potential for drug–drug 
interactions. Fluoxetine was reduced to 40mg 
daily starting on Hospital Day 1, reduced 
to 20mg daily on Hospital Day 3, and was 
discontinued on Hospital Day 8 due to suspected 
contribution to movement disorder. Clonazepam 
was reduced to 0.5mg at bedtime on Hospital 
Day 4, reduced to 0.25mg at bedtime on 
Hospital Day 8, and discontinued on Hospital 
Day 12 to reduce fall risk. He demonstrated 
gradual improvement of choreoathetoid 
movements over a one-week period, resulting 
in the ability to ambulate without the assistance 
of arm weights, leg weights, and a weighted 
walker. Despite remarkable improvement, the 
patient still experienced mild choreoathetoid 
movements, speech spasticity, and behavioral 
disinhibition. Results from the HD DNA 
sequence returned positive (45 CAG repeats) 
on Hospital Day 8 and a formal diagnosis of HD 
was made. On Hospital Day 21, oral melatonin 
5mg was initiated nightly for new onset 
insomnia. Following two nights of melatonin, 
increased choreoathetoid movements were 
observed by nursing staff, leading to melatonin 
discontinuation. Movements returned to 
baseline one day following discontinuation 
of melatonin. The patient was discharged, on 
olanzapine 10mg nightly, to a group home on 
Hospital Day 27 with significantly improved 
choreoathetoid movements, ability to ambulate, 
and handwriting (Figure 1).
Following discharge, the patient’s past 
three years of outpatient medical records were 
reviewed independently by three authors of 
this article (CH, IM, and RM). These records 
revealed that three years prior to the previously 
described hospitalization, fluoxetine had 
been titrated from 20mg to 60mg daily over 
a three-month period and continued until 
admission. During fluoxetine titration, the 
patient experienced significant decrease in 
coordination, falls, and increased hyperactivity. 
Two years prior to the previously described 
hospitalization, lisdexamfetamine was initiated 
and titrated both upward and downward, in 
which he experienced worsening chorea and 
psychomotor agitation at higher doses. There 
was no documentation that the patient had 
previously taken melatonin. Finally, genetic 
testing revealed the patient to be a cytochrome 
P450 (CYP) 2D6 poor metabolizer, though no 
other CYP450 test results were available. 
DISCUSSION
The reported patient presented with HD-
related chorea that initially was exacerbated 
by fluoxetine, worsened with addition of 
lisdexamfetamine, and significantly improved 
after discontinuation of both medications 
at hospital admission. These findings were 
supported per review of the patients past three 
years of outpatient medical records. As the 
patient had attended an outpatient psychiatric 
clinic on approximately a monthly basis, 
documentation of worsening or improvement 
of movement-related side effects were clearly 
documented. Unfortunately, due to an absence 
of an HD diagnosis at the time, and desires 
to aggressively treat the patient’s apathy 
and depressive symptoms, fluoxetine and 
lisdexamfetamine were likely overlooked for 
causing choreoathetosis exacerbation. In light 
of this patient’s CYP 2D6 poor metabolizer 
status, it would also be expected that his 
plasma concentrations of fluoxetine and 
lisdexamfetamine would be elevated compared 
to a CYP 2D6 extensive (normal) metabolizer. 
Additionally, because fluconazole is a CYP 2C9 
inhibitor, it is plausible that it further increased 
fluoxetine concentration, a CYP 2C9 and 2D6 
substrate.15 These CYP450 pharmacokinetic 
interactions likely increased his risk for 
movement-related adverse events. At first 
glance, the slow and progressive improvement 
of choreoathetosis after both drugs were 
discontinued could be best explained by the 
discontinuation of fluoxetine, which has an 
elimination half-life of 4 to 6 days for the parent 
drug and 4 to 16 days for the active metabolite, 
norfluoxetine, after chronic administration.12 
However, a previous case report of 
psychostimulant-induced chorea described 
symptoms that persisted up to 72 hours after 
drug discontinuation, and in the context of 
our patient being a CYP 2D6 poor metabolizer, 
delayed lisdexamfetamine elimination should 
also be considered.16
We find it probable that worsening 
choreoathetosis occurred secondary to 
fluoxetine use (Naranjo 17 score=5) due to 
previous reports of this reaction, outpatient 
medical records documenting an exacerbation 
of symptoms within two months following 
fluoxetine initiation in the absence of a 
psychostimulant, worsened coordination, 
increased falls, hand-flapping, and psychomotor 
agitation upon dose increases of fluoxetine, 
FIGURE 1. Patient’s handwriting sample—A) At hospital admission while taking fluoxetine and lisdexamfetamine; B) 
At hospital discharge after the discontinuation of fluoxetine and lisdexamfetamine
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and marked improvement following drug 
discontinuation. Fluoxetine has previously been 
associated with a number of extrapyramidal 
movement disorders,10 and the effects of 
antidepressants on HD-related chorea are 
unclear. In a large sample of prodromal HD 
subjects, an association was found between 
antidepressant use and motor symptom 
progression; however, there are a number of 
explanations for this, including worsening 
affective symptoms secondary to disease 
progression.18 A randomized, double-blind 
trial of 30 nondepressed subjects with HD 
received fluoxetine 20mg/day or placebo, 
of which 12 subjects receiving fluoxetine 
completed the trial. A trend toward worsening 
resting chorea, eye movements, and maximum 
chorea occurred with fluoxetine compared to 
placebo.19 Additionally, a patient with HD had 
an exacerbation of chorea after two weeks 
of fluoxetine 20 mg/day that abated after 
discontinuation.14 Alternatively, a report of 
two patients with HD described improvement 
of choreiform movements after initiation of 
fluoxetine 20mg/day.20 The causes for these 
contradictory responses to fluoxetine in these 
reports is uncertain, but this has also been 
reported with DA agonists and antagonists.4,14,20 
The variable response could be due to differences 
between HD progression between patients.4 
We find it probable that lisdexamfetamine 
contributed to choreoathetosis (Naranjo 
score=5) in our patient, based previous reports 
of this reaction, previous medical records 
documenting exacerbation of symptoms 
after psychostimulant initiation, worsened 
chorea with dosage increases, improved 
coordination and psychomotor agitation upon 
dosage decreases, and marked improvement 
following drug discontinuation.17 Several case 
reports have described young children who 
developed chorea or dyskinesia following 
consumption of psychostimulants.13,16,21,22 
These movement disorders either responded 
to dopaminergic blocking agents or resolved 
spontaneously within 12 to 72 hours with no 
pharmacologic intervention.16,21,22 Another 
young child with attention-deficit/hyperactivity 
disorder demonstrated dysarthria, tremor, 
and increased extremity tone after four weeks 
of methylphenidate therapy.13 These adverse 
events prompted HD DNA testing, where he 
was found to have 75 CAG repeats, confirming 
a diagnosis of HD.13 Despite cases of chorea, 
dyskinesia, and potential unmasking HD 
in childhood, as well a dearth of evidence 
from clinical studies, psychostimulants have 
been recommended to treat apathy in HD.9 
Certainly this practice should only be conducted 
with significant caution and monitoring for 
worsening of movement-related symptoms. 
Later, during hospitalization, our patient 
experienced worsening of chorea after 
administration of a two-day trial of exogenous 
melatonin, which improved after melatonin 
discontinuation. As exogenous melatonin has 
not been studied in HD, was never previously 
utilized by our patient, nor been previously 
described to worsen chorea, it is possible 
(Naranjo score=2) that melatonin caused 
worsening choreoathetosis.17 Indeed, HD rat 
model studies indicate that melatonin can act 
as a neuroprotectant in HD.23,24 The fact that the 
choreatic movements increased rapidly after 
administration of melatonin and subsided after 
discontinuation of use suggests that melatonin 
might modulate the pharmacological response 
linked to motor alterations. Since the core of 
motor alterations in HD are apparently rooted 
in neurochemical changes in DA, effects of 
melatonin in dopaminergic signaling could 
impact this relationship. There exists a biphasic 
nature of DA in the behavioral pathology of HD. 
Early in the disease, increased DA signaling is 
associated with choreatic dysfunction, while 
later in the disease low DA signaling manifests 
TABLE 1. Using the Naranjo Adverse Drug Reaction Probability Scale, worsening choreoathetosis was deemed probable, 
probable, and possible for fluoxetine (F), lisdexamfetamine (L), and melatonin (M) use, respectively
QUESTIONS F L M
1
Are there previous conclusive reports on this reaction? 
Yes (+1); No (0); Do not know or not done (0)
1 1 0
2
Did the adverse events appear after the suspected drug was given?
 Yes (+2); No (-1); Do not know or not done (0)
2 2 2
3
Did the adverse reaction improve when the drug was discontinued or a specific antagonist was 
given?  Yes (+1); No (0); Do not know or not done (0)
1 1 1
4
Did the adverse reaction appear when the drug was readministered? 
Yes (+2); No (-1); Do not know or not done (0)
0 0 0
5
Are there alternative causes that could have caused the reaction? 
Yes (-1); No (+2); Do not know or not done (0)
-1 -1 -1
6
Did the reaction reappear when a placebo was given?
Yes (-1); No (+1); Do not know or not done (0)
0 0 0
7
Was the drug detected in any body fluid in toxic concentrations? 
Yes (+1); No (0); Do not know or not done (0)
0 0 0
8
Was the reaction more severe when the dose was increased, or less severe when the dose was 
decreased? Yes (+1); No (0); Do not know or not done (0)
1 1 0
9
Did the patient have a similar reaction to the same or similar drugs in any previous exposure?
 Yes (+1); No (0); Do not know or not done (0)
0 0 0
10
Was the adverse event confirmed by any objective evidence? 




≥9=definite ADR; 5–8=probable ADR; 1–4=possible ADR; 0=doubtful ADR 5 5 2
ADR: adverse drug reaction
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as akinesia.24,25 To explain the overt appearance 
of choreatic movements in our patient, we 
need to identify the possible changes in the 
DA system after melatonin administration. 
While melatonin enhances DA release, this 
phenomenon was only evident in retina and 
not in striatum, a region clearly linked to 
motor behavior.26 The short-term exposure to 
melatonin and subsequent rapid attenuation 
of the effects after discontinuation argue 
against irreversible neurotoxicological effects. 
Interestingly, a study done in rats identified an 
increase in DA receptor affinity with no changes 
in total receptor expression in striatum after 
exposure to melatonin.11 This type of allosteric 
modification could explain the exacerbation 
of the motor deficits, as equivalent levels 
of DA will lead to enhanced postsynaptic 
response. Additionally, melatonin could also 
enhance DA synthesis because it has been 
demonstrated to increase levels and activity of 
tyrosine hydroxylase, the rate-limiting enzyme 
in DA synthesis.27 Thus, the combined effect 
of increased DA synthesis and enhanced DA 
receptor affinity possibly contributed to the 
worsening chorea seen in our patient. 
Limitations. There are several limitations 
to this case report. First, we retrospectively 
reviewed outpatient clinic notes to correlate 
previous medication trials with movement 
disorder symptoms. While these notes were 
detailed and well documented, there could 
have been omissions in documentation, 
and no specific movement disorder severity 
scales were available. Second, the Naranjo 
Adverse Drug Reaction Probably Scale was 
not designed to assess multiple medication 
contributions to a specific adverse event.17 
In this context, and in our case, medications 
are to be scored individually and the drug 
with the highest Naranjo score is most likely 
the causative agent for the adverse event.17 
Fluoxetine and lisdexamfetamine had the 
same Naranjo score in our case, and we believe 
both contributed equally to the adverse 
event. Third, due to cognitive deficits, the 
patient had poor memory of his responses to 
medications prior to admission. Fourth, we 
did not perform therapeutic drug monitoring 
in this patient. Serum concentrations of 
fluoxetine, norfluoxetine, lisdexamfetamine, 
and dextroamphetamine obtained at hospital 
admission could have provided useful data 
when considering the aforementioned drug–
drug interactions and CYP 2D6 poor metabolizer 
phenotype. Due to these limitations, we cannot 
establish causality of adverse events reported. 
Limitations notwithstanding, the patient was 
ultimately grateful for the care he received 
by our inpatient service and for his robust 
improvements in ambulation and coordination 
at hospital discharge.
CONCLUSION
Our case is the second to describe worsened 
choreoathetoid movements with fluoxetine 
and psychostimulants in HD, and the first with 
melatonin. These observations are objectified 
by our patient’s marked improvements in 
movement and handwriting assessments 
(Figure 1). We calculated Naranjo adverse 
event scores of 5, 5, and 2 for fluoxetine, 
lisdexamfetamine, and melatonin, respectively, 
based on several years of this individual’s 
outpatient medical records and current available 
literature (Table 1). Due to physiological and 
biochemical changes associated with HD 
progression, these medications could have 
different effects depending on HD staging. 
Melatonin has shown to be neuroprotective 
in toxicological and genetic models of HD, but 
it has not been studied in humans. However, 
if these neuroprotective effects hold true, 
there might be a possible use of melatonin in 
the late akinetic stages of HD. Fluoxetine and 
lisdexamfetamine appear to have worsened 
this patient’s chorea, likely due to their 
dopaminergic effects and presumed increased 
serum concentrations caused by this patient’s 
status as a CYP 2D6 poor metabolizer and other 
drug–drug interactions. Based on this, it might 
be prudent to use caution when initiating 
psychostimulants, fluoxetine, or melatonin in 
patients with known early-to-middle stage 
HD. Also, individuals who present with new or 
worsened choreoathetoid movements following 
administration of lisdexamfetamine, fluoxetine, 
or melatonin who have not been diagnosed 
with HD and have an unclear family history 
of HD might benefit from genetic testing to 
assess for presence of HD. We suggest vigilant 
monitoring for changes in motor function 
and frequent reassessment of medications 
over time in an attempt to account for 
fluctuations in dopaminergic activity and DA 
receptor sensitivity in the later stages of HD. 
Randomized withdrawal trials with melatonin, 
antidepressant, and/or psychostimulant in 
patients with HD that assess for changes in 
chorea would likely be worthwhile. Placebo-
controlled crossover trials could also be utilized 
to further determine if our observations are 
generalizable.
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